Replies to post #116702 on NanoViricides Inc. (NNVC)

[BonelessCat]

Not correct. It is a poison pill to prevent hostile takeovers. Controlled buyouts through negotiating terms are still quite doable. The problem for shareholders is that Theracour will also be at the negotiating table regarding terms of the IP transfer, both from the Theracour side as well as the acquisition of NNVC's rights to license.

What buyout? Theracour owns all the IP. It's a poison pill designed precisely to prevent buyouts.

Also, while I'm posting, there is no recommended pre-IND meeting for topical drugs. The preclinical development requirements are pretty straight forward and far less cumbersome than oral or IV drug delivery. One sticking point in the FDA guidance is the requirement for data on penetrability and controlled in vitro release testing. This gets into challenges for nano-molecules (mega-molecular structures) that have a high membrane penetrability.

Anyway, just pointing out flaws in posted claims.

One source for the above: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM070930.pdf